Animal diseases

JBS Couros launches antiviral leather

Retrieved on: 
Thursday, July 22, 2021
Sarbecovirus, Animal diseases, Infectious diseases, Medical specialties, Bat virome, Severe acute respiratory syndrome, Antiviral drug

SÃO PAULO, July 22, 2021 /PRNewswire/ -- JBS Couros has announced the launch of JBS V-Block technology, which inactivates the SARS-Cov-2 virus, the cause of Covid-19. At processing stage, a silver microparticle additive is added to the leather coating   providing it with antiviral qualities.

Key Points: 
  • SO PAULO, July 22, 2021 /PRNewswire/ --JBS Couros has announced the launch of JBS V-Block technology, which inactivates the SARS-Cov-2 virus, the cause of Covid-19.
  • At processing stage, a silver microparticle additive is added to the leather coating providing it with antiviral qualities.
  • "Our leather has undergone scientific tests that prove the inactivation of the SARS-Cov-2 virus.
  • "The use of this technology increases the contact surface of silver and its prominence in the leather, enabling antiviral action," says researcher Lucio Freitas, who participated in the tests of the new material.

GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting

Retrieved on: 
Thursday, July 22, 2021
Medical specialties, Animal diseases, Infectious diseases, Zoonoses, Biological weapons, Tropical diseases, Sudan ebolavirus, Ebolavirus, Ebola, GeoVax, Zaire ebolavirus, Filoviridae

ATLANTA, GA, July 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines, today announced the presentation of data from a study of its preventive vaccine against Sudan Ebolavirus (SUDV). The presentation titled “A single immunization of guinea pigs with a modified vaccinia Ankara virus producing Sudan virus-like particles protects from Sudan virus lethal challenge,” was delivered by Dr. Delphine Malherbe of the Bukreyev Lab, Department of Pathology, University of Texas Medical Branch, Galveston, Texas, during the Annual Meeting of the American Society for Virology, being held virtually July 19-23.

Key Points: 
  • Challenge of vaccinated animals with guinea pig-adapted SUDV demonstrated a complete protection against death and disease by the prime and the prime-boost regimens.
  • This is the first report that a replication-deficient MVA vector may confer full protection against SUDV after a single dose.
  • David Dodd, GeoVax President and CEO, further commented, The presentation of data from this study further validates our platform and approach to addressing Sudan virus, and we look forward to advancing our vaccine to non-human primate testing.
  • Sudan ebolavirus (SUDV) is one of six known viruses within the genus Ebolavirus (Filoviridae family) and causes Ebola virus disease in humans, with a fatality rate up to 73%.

eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent

Retrieved on: 
Thursday, July 22, 2021
Coronaviridae, Zoonoses, Animal diseases, Sarbecovirus, Antiviral drugs, Human coronavirus 229E, Severe acute respiratory syndrome coronavirus 2, Coronavirus, Coronavir, COVID-19, Middle East respiratory syndrome–related coronavirus, Severe acute respiratory syndrome coronavirus

The Phase 1b trial is a double-blind, randomized dose escalation trial in non-hospitalized patients ages 18-65 with mild to moderate COVID-19.

Key Points: 
  • The Phase 1b trial is a double-blind, randomized dose escalation trial in non-hospitalized patients ages 18-65 with mild to moderate COVID-19.
  • Further, in vitro studies have shown that zotatifin has potent antiviral activity across all unique coronavirus subtypes tested, including SARS-CoV-2, SARS-CoV-1, MERS-CoV and CoV-229E.
  • Zotatifin, eFFECTORs inhibitor of eIF4A, has recently completed the dose-escalation portion of a Phase 1/2 trial, and is now progressing into Phase 2a indication-specific expansion cohorts.
  • Neither LWAC nor eFFECTOR gives any assurance that either LWAC or eFFECTOR or the combined company will achieve its expectations.

EPA Approves Mass Transit Air Treatment Solution for Texas, Nevada, Pennsylvania and Maryland

Retrieved on: 
Monday, July 19, 2021
Zoonoses, Health, Animal diseases, Sarbecovirus, Biocides, Epidemiology, Infectious diseases, Antimicrobial, COVID-19, Severe acute respiratory syndrome, Virus

Administered through Luminator Technology Group 's (Luminator) Renew Air Treatment System , the solution provides continuous protection against SARS-CoV-2, the virus that causes COVID-19.

Key Points: 
  • Administered through Luminator Technology Group 's (Luminator) Renew Air Treatment System , the solution provides continuous protection against SARS-CoV-2, the virus that causes COVID-19.
  • Approved use sites in Texas, Nevada, Pennsylvania and Maryland include intrastate transportation.For a complete listing of approved use sites, please visit EPA's website .
  • Luminator's Renew Air Treatment System dispenses the antimicrobial air treatment through a connected, technologically advanced system that measures and automatically adjusts the amount of Grignard Pure that is dispensed.
  • "We know now with certainty that the virus is airborne, and an antimicrobial air treatment solution is needed to combat the virus particles.

Physician-Scientist Steven Quay and an International Team of Scientists and Investigators Provide Science-Based Analysis of the Origin of COVID-19 to the US Congress

Retrieved on: 
Thursday, July 15, 2021
Articles, Health, Global health, Zoonoses, Infectious diseases, Epidemiology, Animal diseases, Zoonosis, Coronavirus, Virus, Pandemic, Emergent virus

Unlike with previous natural zoonotic epidemics, there was no evidence of pre-pandemic animal-to-human transmission and no evidence of an intermediate animal host.

Key Points: 
  • Unlike with previous natural zoonotic epidemics, there was no evidence of pre-pandemic animal-to-human transmission and no evidence of an intermediate animal host.
  • "A research-related accident involves a single transmission of a pure virus to one human and then human-to-human spread," said Dr. Quay.
  • Dr. Steven Quay has 360+ published contributions to medicine and has been cited over 10,000 times, placing him in the top 1% of scientists worldwide.
  • He is the author of the best-selling book on surviving the pandemic, Stay Safe: A Physician's Guide to Survive Coronavirus.

Genetron Health Receives CE Mark for 8-Gene Lung Cancer Assay and Provides FDA Reference Panel Comparative Data of its SARS-CoV-2 RNA Test

Retrieved on: 
Tuesday, July 13, 2021
Sarbecovirus, Zoonoses, Animal diseases, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Infectious diseases, Medicine

Separately, the Company also reported comparative data showing the sensitivity performance of the Genetron SARS-CoV-2 RNA Test.

Key Points: 
  • Separately, the Company also reported comparative data showing the sensitivity performance of the Genetron SARS-CoV-2 RNA Test.
  • The CE Mark represents the second regulatory milestone for 8-gene Lung Cancer Assay, as it is already approved by Chinas NMPA and is being commercialized in China.
  • We are excited to receive the CE Mark, which represents an important new commercialization opportunity for our 8-gene Lung Cancer Assay.
  • Separately, the Company also reported comparative performance data of its SARS-CoV-2 RNA Test based on a SARS-CoV-2 reference panel established by the U.S. Food and Drug Administration (FDA).

Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Retrieved on: 
Wednesday, June 30, 2021
Animal diseases, Fungal diseases, Infectious diseases, Sepsis, Antifungals, Echinocandin, Invasive candidiasis, Candidiasis, Fungemia, Mycosis, Draft:David Wemyss Denning, Candida albicans

Rezafungin is a novel once-weekly echinocandin currently being studied in Phase 3 trials for the treatment and prevention of serious fungal infections incriticallyilland cancer patients.

Key Points: 
  • Rezafungin is a novel once-weekly echinocandin currently being studied in Phase 3 trials for the treatment and prevention of serious fungal infections incriticallyilland cancer patients.
  • Rezafungin is a novel once weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.
  • The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients.
  • Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.

Pardes Biosciences and FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Advancing Oral Antiviral Drugs to Treat and Prevent SARS-CoV-2 Infections

Retrieved on: 
Tuesday, June 29, 2021
Infectious diseases, Biotechnology, Pharmaceutical, Health, Bat virome, Sarbecovirus, Severe acute respiratory syndrome, Animal diseases, Infectious diseases, Medical specialties, Pardes Biosciences, FS Development Corp. II (FSII), PARDES BIOSCIENCES, FS DEVELOPMENT CORP. II (FSII)

Pardes Biosciences, Inc., an early-stage biopharmaceutical company, and FS Development Corp. II (Nasdaq: FSII), a special purpose acquisition company sponsored by Foresite Capital, today announced they have entered into a definitive merger agreement.

Key Points: 
  • Pardes Biosciences, Inc., an early-stage biopharmaceutical company, and FS Development Corp. II (Nasdaq: FSII), a special purpose acquisition company sponsored by Foresite Capital, today announced they have entered into a definitive merger agreement.
  • The proposed transaction has been approved by the boards of Pardes Biosciences and FS Development Corp. II, including all of their disinterested directors.
  • Pardes Biosciences is an agile biopharmaceutical company committed to solving some of the worlds most pressing public health challenges.
  • The companys lead product candidate, PBI-0451, is being developed as a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections.

Therma Bright to Test AcuVid(TM) on the Highly Contagious COVID-19 Delta Variant, Company Completes Brazilian Clinical Study for Final FDA EUA Submission

Retrieved on: 
Thursday, June 24, 2021
Respiratory diseases, Animal diseases, Medical specialties, Occupational safety and health, Atypical pneumonias, COVID-19, Public health, Zoonoses, Severe acute respiratory syndrome

Governments and global health experts have expressed deep concerns that the highly contagious, fast spreading Delta variant will add to a new wave of COVID-19 viral infections globally later this summer and fall.

Key Points: 
  • Governments and global health experts have expressed deep concerns that the highly contagious, fast spreading Delta variant will add to a new wave of COVID-19 viral infections globally later this summer and fall.
  • "We are excited that our Brazilian clinical study has now met the minimum FDA-EUA requirements for our submission to secure serial testing approval," expressed Rob Fia, Therma Bright's CEO.
  • Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.
  • Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs.

SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets)

Retrieved on: 
Wednesday, June 23, 2021
Animal diseases, Antifungals, Ibrexafungerp, Pyridines, Branches of biology, VVC, Medical specialties, Vaginal yeast infection, Candidiasis, Forward-looking statement, Vagina

BREXAFEMME is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC), or vaginal yeast infections.

Key Points: 
  • BREXAFEMME is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC), or vaginal yeast infections.
  • Dr. Taglietti has served as Chief Executive Officer of SCYNEXIS since April 2015 and became President of the Company in September 2015.
  • Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: the BREXAFEMME launch update and the second half 2021 commercial plan for BREXAFEMME.
  • SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.